ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug approval disease medicine developmental biology ecology

Guts and Glory
Anna Azvolinsky | Apr 1, 2016 | 9 min read
An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.
5 images related to stories highlighted in the article, including DNA strand, insect, and dog
Our Favorite Genetics Stories of 2021
Christie Wilcox, PhD | Dec 23, 2021 | 4 min read
Studies The Scientist covered this year illustrate the expanding importance of genetic and genomic research in all aspects of life science, from ecology to medicine.
Image of the tissue surrounding a pancreatic tumor thickening and scarring.
How Pancreas Injuries Can Cause Cancer in Mice
Dan Robitzski | Nov 9, 2021 | 4 min read
A key mutation turns healing cells into cancer promoters.
The Ecology of Tumors
Paraic A. Kenny, Celeste M. Nelson, and Mina J. Bissell | Apr 1, 2006 | 10+ min read
FEATUREThe Ecology of Tumors   Courtesy of Nasa Ames Research CenterBy perturbing the microenvironment, wounds and infection may be key to tumor development.BY PARAIC A. KENNY, CELESTE M. NELSON, AND MINA J. BISSELLNo tumor is an island. Chemical and physical forces exerted by the diverse cellular populations that surround a tumor - its so-called microenvironment - shape development and progression. Manipulating these 'ecologi
Weathering Hantavirus: Ecological Monitoring Provides Predictive Model
Steve Bunk | Jul 4, 1999 | 7 min read
Photo: Steve Bunk Dave Tinnin, field research associate in the University of New Mexico's biology department, takes blood samples and measurements of rodents caught on the research station grounds. At the end of a freeway exit near Soccoro, N.M., the hairpin turn onto a gravel road is marked by a sign that warns, "Wrong Way." But it isn't the wrong way if you want to reach the University of New Mexico's (UNM) long-term ecological research (LTER) station. The sign's subterfuge is the first indi
Alternative Medicines
The Scientist | Jul 1, 2012 | 10+ min read
As nonconventional medical treatments become increasingly mainstream, we take a look at the science behind some of the most popular.
The Challenges of Rare-Disease Research
Jyoti Madhusoodanan | Sep 1, 2016 | 8 min read
With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.
Can Destroying Senescent Cells Treat Age-Related Disease?
Katarina Zimmer | Mar 1, 2020 | 10+ min read
A handful of clinical trials are underway to find out whether drugs that target senescent cells can slow the ravages of old age.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Can FDA Reform Drug Reviews?
Steve Bunk | Mar 15, 1998 | 8 min read
Date: March 16, 1998 New Drug Development A regional lab visit highlights challenges of agency-wide change At the Food and Drug Administration's Central Region office in Philadelphia, cabinetsful of documentation offer only a vague notion of the paperwork involved in getting a new drug through FDA's review and approval process. Nicholas Falcone, the district office's coordinator of new drug applications (NDAs) and abbreviated new drug applications (ANDAs)-the latter for generic compounds-hefts

Run a Search

ADVERTISEMENT